BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Anthony Elgamal: Redefining First-Line Treatment in EGFR-Mutated Lung Cancer

BioPharma APAC speaks with Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific, on th...

October 13, 2025 | Expert Insight

Henlius’ HANSIZHUANG Meets Primary Endpoint in Phase 3 Gastric Cancer Trial

The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Applicati...

October 13, 2025 | News

Renalys Pharma Completes Primary Endpoint Data Collection in Phase III Sparsentan Trial for IgA Nephropathy

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced that it has completed data collection for the primary endpoint in the Phase I...

October 13, 2025 | News

Berlin Heals Completes Enrollment in First-in-Human Study of Less Invasive Heart Failure Therapy

Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a major Cardiology Congress ...

October 13, 2025 | News

Ono Pharma Reports Positive Phase 2 Signals for ONO-2808 in Multiple System Atrophy

Efficacy signals were observed in an interim analysis of a Phase 2 clinical trial for ONO-2808, a S1P5 receptor agonist Phase 2 clinical trial was con...

October 13, 2025 | News

C-Ray Therapeutics Commends Biokin on NMPA Approval for Groundbreaking [177Lu]-BL-ARC001 Radiopharmaceutical

C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the N...

October 13, 2025 | News

Chance Pharmaceuticals and Huadong Medicine Partner for Exclusive Commercialisation of CXG87 in China

Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhala...

October 10, 2025 | News

Australia’s Cyteph Completes Recruitment for Its First-in-Human Trial of CYT-101 in Glioblastoma

Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed...

October 09, 2025 | News

Kazia Therapeutics Partners with QIMR Berghofer to Develop First-in-Class PD-L1 Degrader NDL2

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced an exclusive collaboration and in-licensing agreem...

October 09, 2025 | News

AbbVie’s BOTOX® Achieves Primary and Secondary Endpoints in Phase 2 ELATE Trial for Essential Tremor

OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement ...

October 07, 2025 | News

ExQor Technologies Prepares for Clinical Trials of Regenerative Platform Aiming to Reverse Alzheimer’s Damage

ExQor Technologies, a Boston MA based biotechnology company, is preparing for clinical trials for its proprietary brain regenerative medicine pla...

October 06, 2025 | News

Health Hope Pharma and Hanmi Grant Gilead Global Rights to Encequidar in Virology

Health Hope Pharma Limited announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") for ence...

September 30, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU delivers second positive phase 3 win in HER2 positive early breast cancer

Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become...

September 30, 2025 | News

AbbVie Submits FDA Application for Tavapadon After Positive Phase 3 TEMPO Results in Parkinson’s Disease

Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive r...

September 29, 2025 | News

Stay Connected